P&G Actonel Payment Postponed: $50 Mil. Delay Contributes To $40 Bil. Drop
Executive Summary
The delay in the approval of Procter & Gamble's Actonel for osteoporosis contributed to the company's $38.7 bil. drop in value following the March 7 announcement that it will miss its earnings targets.